Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca aims to offset drug setback at big cancer congress

After a big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation in September 2017 when it unveils full details of two key clinical trials tackling the disease in different ways.

Read More »

Advertising budget for Obamacare to be cut 90 percent: U.S. health agency

The U.S. Centers for Medicare and Medicaid Services said it plans to spend $10 million on advertising for the upcoming Obamacare open enrollment period that starts in November 2017, a sharp cut from the $100 million spent during 2016.

Read More »

Profit on $475,000 Novartis cancer drug could be a while coming

Novartis’s new gene-modifying cancer therapy’s $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.

Read More »

Arizona accuses drugmaker Insys of fraudulent opioid marketing

Arizona sued Insys Therapeutics Inc., accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine called Subsys.

Read More »

Daiichi Sankyo Terminates $650 Million Deal With Charleston Laboratories

After three years Daiichi Sankyo called it quits regarding the company’s partnership with Charleston Laboratories and took a loss of about $250 million.

Read More »

Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.’s Keytruda

Incyte Corporation will have an abstract published at the European Society for Medical Oncology (ESMO) meeting in early September with new and updated data from its ongoing Phase I/II trial of epacadostat in combination with Merck & Co.’s Keytruda in advanced melanoma.

Read More »

Daiichi Sankyo denies AstraZeneca takeover bid

Japanese drugmaker Daiichi Sankyo denied that it received a takeover bid during 2016 from Britain’s AstraZeneca.

Read More »

Amazon hit with lawsuit over eclipse glasses was hit with a proposed class action lawsuit by a couple who claims defective eclipse glasses purchased through the online retailer damaged their eyes.

Read More »

FDA Approves Austedo for Tardive Dyskinesia

Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.

Read More »

Lack of REM sleep tied to increased risk of dementia

People who spend less time in deep, rapid eye movement (REM) sleep may be more likely to develop dementia than individuals who get better quality rest, a recent study suggests.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom